RLMD

Relmada Therapeutics, Inc.

3.37 USD
+0.03 (+0.90%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Relmada Therapeutics, Inc. stock is down -15.75% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 May’s closed higher than April. In the last 1 Unusual Options Trades, there were 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
20 Mar 16:18 17 May, 2024 5.00 PUT 332 180

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Its lead product candidate is Esmethadone, a new chemical entity and N-methyl-D-aspartate receptor antagonist.